# US 2019/0167610 A1 · Triple Combination Formulation for Treatment of Chronic Pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167610 A1
- Document ID: US20190167610A1
- Status: Published application
- Kind: A1
- Application number: 16/209,261
- Filed: 2018-12-04
- Published: 2019-06-06
- Earliest claimed: 2017-12-04
- Assignees: Northwestern University; University of Notre Dame du Lac
- Applicants: Northwestern University; The University of Notre Dame Du Lac
- Inventors: A. Vania Apkarian; Kasturi Haldar; Suhail Alam; Maria Virginia Centeno
- Web page: https://patentgrep.com/patent/US20190167610A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to use of a triple formulation comprising a histone deacytlase, a cyclodextrin and polyethylene glycol or propylene glycol, and in the treatment and management of chronic pain.

## Claims

### Claim 1

A method of treating chronic pain in a subject in need thereof, the method comprising administering to the subject a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol, wherein the composition is provided in a therapeutically effective amount to treat the chronic pain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is vorinostat.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cyclodextrin is 2-hydroxypropyl-b-cyclodextrin (HPBCD).

### Claim 4 (depends on 1)

The method of claim 1, wherein the polyethylene glycol (PEG) or propylene glycol is polyethylene glycol.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises a molar ratio of HDAC inhibitor:cyclodextrin:PEG of about 1-100:1-1000:1-1000.

### Claim 6 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is present in an administration amount of about 0.1-500 mg/kg, cyclodextrin is present in an administration amount of about 1000-40,000 mg/kg, and the PEG is present in an amount of about 30-60% composition by weight.

### Claim 7 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is vorinostat at an administration amount of about 50 mg/kg, the cyclodextrin is HPBCD at an administration amount of at about 2000 mg/kg, and PEG is about 40-50% composition by weight.

### Claim 8 (depends on 1)

The method of claim 1, wherein the chronic pain comprises one or more of, chronic nociceptive pain, chronic neuropathic pain, chronic inflammatory pain, arthritis pain, fibromyalgia, breakthrough pain, persistent pain, hyperalgesia, allodynia, central sensitization, peripheral sensitization, disinhibition and augmented facilitation, or cancer pain.

### Claim 9

A method of reducing or inhibiting one or more symptoms of chronic pain, the method comprising administering to the subject a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol, wherein the composition is provided in a therapeutically effective amount to reduce or inhibit one or more symptom of chronic pain.

### Claim 10 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor is vorinostat.

### Claim 11 (depends on 9)

The method of claim 9, wherein the cyclodextrin is 2-hydroxypropyl-b-cyclodextrin (HPBCD).

### Claim 12 (depends on 9)

The method of claim 9, wherein the polyethylene glycol (PEG) or propylene glycol is polyethylene glycol.

### Claim 13 (depends on 9)

The method of claim 9, wherein the composition comprises a molar ratio of HDAC inhibitor:cyclodextrin:PEG of about 1-100:1-1000:1-1000.

### Claim 14 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor is present in an administration amount of about 0.1-500 mg/kg, cyclodextrin is present in an administration amount of about 1000-40,000 mg/kg, and the PEG is present in an amount of about 30-60% composition by weight.

### Claim 15 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor is vorinostat at an administration amount of about 50 mg/kg, the cyclodextrin is HPBCD at an administration amount of at about 2000 mg/kg, and PEG is about 40-50% composition by weight.

### Claim 16 (depends on 9)

The method of any one of claim 9, wherein the chronic pain comprises one or more of, chronic nociceptive pain, chronic neuropathic pain, chronic inflammatory pain, fibromyalgia, breakthrough pain, persistent pain, hyperalgesia, allodynia, central sensitization, peripheral sensitization, disinhibition and augmented facilitation, or cancer pain.

### Claim 17

Use of a composition comprising (i) a histone deacetylase (HDAC) inhibitor, (ii) a cyclodextrin or salt thereof, and (iii) polyethylene glycol (PEG) or propylene glycol for manufacture of a medicament for the treatment of chronic pain or inhibition of symptoms of chronic pain.

### Claim 18 (depends on 17)

The use according to claim 17, wherein the medicament is prepared to be administered orally, sublingually, vial inhalation, transdermal, subcutaneously, intravenously, intraperitoneally, intra-arterially, intra-articulary, peri-articularly, locally, or intramuscularly.

### Claim 19 (depends on 18)

The use according to claim 18, wherein the medicament is prepared to be orally or intravenously administered.

### Claim 20 (depends on 17)

The use according to claim 17, wherein the HDAC inhibitor is vorinostat, the cyclodextrin is 2-hydroxypropyl-b-cyclodextrin (HPBCD) and polyethylene glycol (PEG) or propylene glycol is polyethylene glycol.

### Claim 21 (depends on 17)

The use according to claim 17, wherein the composition comprises a molar ratio of HDAC inhibitor:cyclodextrin:PEG of about 1-100:1-1000:1-1000.

### Claim 22 (depends on 17)

The use according to claim 17, wherein the HDAC inhibitor is present an administration amount of about 0.1-500 mg/kg, cyclodextrin is present in an administration amount of about 1000-40,000 mg/kg, and the PEG is present in an amount of about 30-60% composition by weight.

### Claim 23 (depends on 17)

The use according to claim 17, wherein the HDAC inhibitor is vorinostat at an administration amount of about 50 mg/kg, the cyclodextrin is HPBCD at an administration amount of at about 2000 mg/kg, and PEG is about 40-50% composition by weight.

### Claim 24 (depends on 17)

The use according to claim 17, wherein the chronic pain comprises one or more of, chronic nociceptive pain, chronic neuropathic pain, chronic inflammatory pain, fibromyalgia, breakthrough pain, persistent pain, hyperalgesia, allodynia, central sensitization, peripheral sensitization, disinhibition and augmented facilitation, or cancer pain.
